Micelles offer non-toxic cancer treatment hopes

The unwanted growth of blood vessels is a key feature of a number of serious diseases including cancers, arthritis and macular degeneration. While there are a number of drugs that effectively inhibit the angiogenesis, or growth, of these vessels some only target a limited number of receptor or have unacceptable side affects.

A team at Boston Children's Hospital have now succeeded in reformulating a broad-spectrum angiogenesis inhibitor, TNP-470, using a nanotechnology approach into a form that can be taken orally and that has the potential to be used as a preventative or maintenance therapy for a variety of cancers.

Whole article nanomednet